Document is current
Any future updates will be listed below
-
Authors
Xiong, Jianping
Ouyang, Weiwei
Yang, Mengxiang
Gao, Zhenyuan
Zhou, Huan
Lou, Hanmei
Guo, Yabing
Xu, Zhongyuan
Zheng, Ling
Liu, Ying
Wang, Zhongfeng
Sun, Ping
Niyazi, Huerxidan
Wang, Jianhua
Chen, Yan
Zhang, Baihui
Li, Lingyan
Kang, Xiaoyan
Guo, Weijian
-
Funding
Funding for this research was provided by:
Qilu Pharmaceutical Co., Ltd funded this study
- License Information
-
More Information
Article History
Received: 19 June 2024
Accepted: 22 August 2024
First Online: 14 September 2024
Declarations
:
: Yan Chen, Baihui Zhang, Lingyan Li, Xiaoyan Kang are affiliated with the sponsoring entity. Their involvement does not influence the integrity and objectivity of the research findings presented in this study. Jianping Xiong, Weiwei Ouyang, Mengxiang Yang, Zhenyuan Gao, Huan Zhou, Hanmei Lou, Yabing Guo, Zhongyuan Xu, Ling Zheng, Ying Liu, Zhongfeng Wang, Ping Sun, Huerxidan Niyazi, Jianhua Wang, and Weijian Guo declare no competing interests.
: The study protocol was approved by Fudan University Shanghai Cancer Center Institutional Review Board (No.2006219-10-2007) and the First Affiliated Hospital of Nanchang University Institutional Review Board (No.2020-029). This study was conducted in compliance with the protocol, and in accordance with the principles of the Declaration of Helsinki as well as the Good Clinical Practice guidelines. This study was registered with clinicaltrials.gov (identifier, NCT05801094).
